Old Web
English
Sign In
Acemap
>
authorDetail
>
Christopher Tehlirian
Christopher Tehlirian
Pfizer
Internal medicine
Placebo
Psoriasis Area and Severity Index
Psoriasis
Clinical endpoint
3
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
2020
Clinical and Translational Science
Ravi Shankar Prasad Singh
Vivek Pradhan
Erika S. Roberts
Matthew Scaramozza
Elizabeth Kieras
Jeremy D. Gale
Elena Peeva
Michael Vincent
Anindita Banerjee
Andrew Fensome
Martin E. Dowty
Peter Winkle
Christopher Tehlirian
Show All
Source
Cite
Save
Citations (4)
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial
2020
Journal of Investigative Dermatology
S. Forman
David M. Pariser
Yves Poulin
Michael S. Vincent
Steven A. Gilbert
Elizabeth Kieras
Ruolun Qiu
Dahong Yu
Jocelyne Papacharalambous
Christopher Tehlirian
Elena Peeva
Show All
Source
Cite
Save
Citations (14)
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
2020
Christopher Tehlirian
Elena Peeva
Elizabeth Kieras
Matthew Scaramozza
Erika S. Roberts
Ravi Shankar Prasad Singh
Vivek Pradhan
Anindita Banerjee
Sandra Garcet
Li Xi
Jeremy D. Gale
Michael Vincent
James G. Krueger
Show All
Source
Cite
Save
Citations (4)
1